COMMUNIQUÉS West-GlobeNewswire

Genovyn Appoints Industry Veterans Sammy Bell as Chief Scientific Officer and Jim Edinger as Chief Development Officer to Accelerate AI-Enabled Therapeutic Discovery and Development
04/06/2026
Leadership appointments fortify Genovyn’s scientific, translational, and development capabilities across its AI-driven platform WILMINGTON, N.C., June 04, 2026 (GLOBE NEWSWIRE) -- GENOVYN, an AI-enabled biotechnology [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Eyeing Nanotech-Driven Delivery Systems, Pharmacokinetic Optimization to Advance Existing Oncology Therapies
04/06/2026
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- via BioMedWire -- Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®
04/06/2026
AHZANTIVE ® (aflibercept) is an EMA-approved biosimilar to Eylea ® (aflibercept) with demonstrated similarity in efficacy, safety and immunogenicity to the reference product The launch expands Teva’s biosimilars [...]
Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules
04/06/2026
First Product Revenue Expected This Month, Opening New Commercial Chapter for Women's Health Innovator Limited-Time Launch Offer: 30% Off + Free Shipping SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc [...]
Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026
04/06/2026
Discussion highlights growing importance on novel ADC payloads, and Akari’s ASCO data in KRAS-driven cancers and future potential Access the Akari CEO Corner here TAMPA, Fla. and LONDON, June 04, 2026 (GLOBE NEWSWIRE [...]
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
04/06/2026
Ready-to-use romidepsin formulation; offers a more convenient alternative to lyophilized powder requiring reconstitution Competitive Generic Therapy approval provides 180 days of market exclusivity and further expands [...]
Melanoma Research Alliance Appoints Stephanie Kauffman as Chief Executive Officer
04/06/2026
WASHINGTON, June 04, 2026 (GLOBE NEWSWIRE) -- The Melanoma Research Alliance (MRA), the world's leading nonprofit funder of melanoma research, today announced the appointment of Stephanie Kauffman as Chief Executive [...]
Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting
04/06/2026
FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as outpatient administration in community hospitals Continued demonstration of [...]
Better Blend Brings a New Kind of Fast Casual to Tampa Bay
04/06/2026
The growing smoothie and bowl concept combines speed and better-for-you options as it enters the region TAMPA, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- What consumers expect from fast casual is changing. While speed and [...]
Cosmos Health Identifies Approximately $20 Million in Non-Core Assets Available for Monetization to Accelerate Growth and Unlock Shareholder Value
04/06/2026
Company identifies real estate, digital assets, and marketable securities, among others, as potential sources of liquidity — with a combined value of approximately $20 million Proceeds could fund a meaningful [...]
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose
04/06/2026
Efforts focus on increasing awareness, expanding access to lifesaving NARCAN® Nasal Spray and reaching more communities with educational initiatives and resources GAITHERSBURG, Md., June 04, 2026 (GLOBE NEWSWIRE) -- In [...]
Weight Watchers to Increase Access to Comprehensive Weight Loss Options for Patients Nationwide through LillyDirect
04/06/2026
LillyDirect customers can now connect to Weight Watchers Med+ program, an integrated GLP-1 access and care model, driving greater weight loss results than medication alone NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- WW [...]
IMUNON Announces Up to $10 Million Cash Financing
04/06/2026
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports IMUNON’s Highly Anticipated Phase 3 OVATION 3 Study of IMNN- [...]
Pure Harvest Corporate Group (OTC: PHCG), Operating as Mixie Technologies, Announces HoloTwin 2.0 Framework for Large-Scale 3D Visualization in the Browser
04/06/2026
With the coming HT Scan capture app, HoloTwin 2.0 forms an end-to-end platform for creating digital twins of buildings and campuses and sharing them across an organization in a standard web browser DENVER, June 04, 2026 [...]
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
04/06/2026
-Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval- -Follows Orphan Drug Designation, Pediatric Rare Disease Designation, and Fast Track [...]
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
04/06/2026
NEW HAVEN, Conn., June 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has recently joined the [...]
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
04/06/2026
MAIA’s novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA [...]
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
04/06/2026
BELTSVILLE, Md., June 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today announced the [...]
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
04/06/2026
FLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular [...]

Pages